| Evommune, Inc. |
Chief Business & Legal Officer |
Common Stock |
60,835 |
$1,085,296 |
$17.84 |
09 Dec 2025 |
Direct |
| Evommune, Inc. |
Chief Business & Legal Officer |
Common Stock |
3,175 |
$59,531 |
$18.75 |
09 Dec 2025 |
By Trust |
| Evommune, Inc. |
Chief Business & Legal Officer |
Employee Stock Option (Right to Buy) |
293,496 |
|
|
05 Nov 2025 |
Direct |
| Anteris Technologies Global Corp. |
Director |
Restricted Stock Units |
13,821 |
|
|
03 Dec 2025 |
Direct |
| Evommune, Inc. |
Chief Business & Legal Officer |
Series B Preferred Stock |
0 |
|
|
07 Nov 2025 |
By Trust |
| Kadmon Holdings, Inc. |
EVP, Gen. Coun. / CCO. |
Common Stock |
0 |
|
$9.50 |
09 Nov 2021 |
Direct |
| Kadmon Holdings, Inc. |
EVP, Gen. Coun. / CCO. |
Equity Appreciation Rights Unit |
0 |
|
$3.50 |
09 Nov 2021 |
Direct |
| Kadmon Holdings, Inc. |
EVP, Gen. Coun. / CCO. |
Performance Stock Option (right to buy) |
0 |
|
$5.44 |
09 Nov 2021 |
Direct |
| Kadmon Holdings, Inc. |
EVP, Gen. Coun. / CCO. |
Stock Appreciation Right |
0 |
|
$5.86 |
09 Nov 2021 |
Direct |
| Kadmon Holdings, Inc. |
EVP, Gen. Coun. / CCO. |
Stock Option (right to buy) |
0 |
|
$5.54 |
09 Nov 2021 |
Direct |